Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma

American Journal of Surgical Pathology

Volumn 22, Issue 8, 1998, Pages 976-982

  Busam, Klaus J ^a   Chen, Yao Tseng ^b   Old, Lloyd J ^a   Stockert, Elisabeth ^a   Iversen, Kristin ^a   Coplan, Keren A ^a   Rosai, Juan ^a   Barnhill, Raymond L ^c   Jungbluth, Achim A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Immunohistochemistry; MART1; Melan A; Melanocytes; Melanoma; Nerve sheath tumor; Nevi

Indexed keywords

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTIC NEVUS; MELANOMA; NERVE SHEATH TUMOR; PROTEIN EXPRESSION; SPINDLE CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM PROTEINS; NEVUS, PIGMENTED; SKIN NEOPLASMS;

EID: 0031904746     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199808000-00007     Document Type: Article

References (36)

1. Barnhill RL, Dickersin GR, Nickeleit V, et al. Studies on the cellular origin of neurothekeoma: clinical, light microscopic, immunohistochemical, and ultrastructural observations. J Am Acad Dermatol 1991;25:80-8.
2. Barnhill RL, Mihm MC Jr. Cellular neurothekeoma. Am J Surg Pathol 1990;14:113-20.
3. Beaty MW, Fetsch P, Wilder AM, Matincola F, Abati A. Effusion cytology of malignant melanoma. A morphologic and immunocytochemical analysis including application of the MART-1 antibody. Cancer 1997;81:57-63.
4. Bonetti F, Colombari E, Zamboni G, et al. Breast carcinoma positive for melanoma marker (HMB-45). Am J Clin Pathol 1989;22: 491-5.
5. Bonetti F, Pea M, Martignoni G, et al. Clear cell ("sugar") tumor of the lung is a lesion strictly related to angiomyolipoma - the concept of a family of lesions characterized by the presence of perivascular epithelioid cells (PEC). Pathology 1994;26:230-6.
6. Bruijn J, Mihm MC Jr, Barnhill RL. Desmoplastic melanoma. Histopathology 1992;20:197-205.
7. Busam KJ, Barnhill RL. Special stains in the evaluation of melanocytic lesions [letter]. Melanoma 1994;12:1-4.
8. Busam KJ, Barnhill RL. Biopsies, tissue processing, and special studies. In: Barnhill RL, ed. Pathology of Melanocytic Nevi and Malignant Melanoma. Boston: Butterworth-Heinemann; 1995:13-20.
9. Busam KJ, Barnhill RL. The immunophenotype of blue nevi [abstract]. J Cutan Pathol 1996;23:68.
10. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to Melan-A (MART-1), in adrenocortical and other steroid tumors. Am J Surg Pathol 1998;22:57-63.
11. Chen Y-T, Stockert E, Jungbluth A, et al. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996;93:5915-9.
12. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
13. DeVries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GNP. Heterogenous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997;57: 3223-9.
14. DuCarlo EF, Woodruff JM, Bansal M, et al. The purely epithelioid malignant peripheral nerve sheath tumor. Am J Surg Pathol 1986; 10:478-90.
15. Fetsch PA, Cromier J, Hijazi YM. Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas. J Immunother 1997;20:60-4.
16. Fetsch PA, Kleiner D, Marincola FM, Abati A. Analysis of melanoma-associated antigen, MART-1, in normal tissues and in selected non-melanomatous neoplasms [abstract]. Modern Pathol 1997;10:43A. Abstract to the 86th annual meeting of the USCAP.
17. Gown A, Vogel A, Hoak D, et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
18. Guccion JG, Enzinger FM. Malignant schwannoma associated with von Recklinghausen's neurofibromatosis. Virchows Arch 1979;383:43-57.
19. Jungbluth AA, Busam KJ, Chen Y-T, et al. A103 - an anti-Melan-A/MART-1 monoclonal antibody for the detection of malignant melanomas in paraffin embedded tissues. Am J Surg Pathol 1998;22:595-602.
20. Kaddu S, Beham A, Cerroni L, et al. Cutaneous leiomyosarcoma. Am J Surg Pathol 1997;9:979-87.
21. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:6458-62.
22. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
23. Kempson RL, McGravan MH. Atypical fibroxanthomas of the skin. Cancer 1964;17:1463-71.
24. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996;19:192-205.
25. Palazzo J, Duray P. Congenital agminated Spitz nevi: immunoreactivity with a melanoma associated antibody. J Cutan Pathol 1988;15:166-70.
26. Pea M, Bonetti F, Zamboni G, Martignoni G, Fiore-Donati L, Doglioni C. Clear cell tumor and angiomyolipoma. Am J Surg Pathol 1991;15:199-202.
27. Prieto VG, Woodruff JM. Expression of HMB-45 antigen in spindle cell melanoma. J Cutan Pathol 1997;24:580-1.
28. Ruiter D, Broeker E-B. Immunohistochemistry in the evaluation of melanocytic tumors. Sem Diagn Pathol 1993;10:76-91.
29. Silvis NG, Swanson PE, Manivel JC, et al. Spindle cell and pleomorphic neoplasms of the skin. A clinicopathological and immunohistochemical study of 30 cases, with emphasis on "atypical fibroxanthomas." Am J Dermatopathol 1988;10:9-19.
30. Smoller BR, McNutt NS, Hsu A. HMB-45 staining of dysplastic nevi. Support for a spectrum of progression towards melanoma. Am J Surg Pathol 1989;13:680-4.
31. Springvall DR, Gu J, Cocchia D, et al. The value of S-100 immunostaining as a diagnostic tool in human malignant melanomas. Virchow Arch Pathol Anat 1983;400:331-44.
32. Sun J, Morton TH, Gown AM. Antibody HMB-45 identifies the cells of blue nevi. An immunohistochemical study on paraffin sections. Am J Surg Pathol 1990;14:748-51.
33. Unger P, Hoffman K, Thung S, et al. HMB-45 reactivity in adrenal pheochromocytomas. Arch Pathol Lab Med 1992;116:151-3.
34. Wick MR, Swanson PE, Scheithauer BW, et al. Malignant peripheral nerve sheath tumor. An immunohistochemical study of 62 cases. Am J Clin Pathol 1987;87:425-533.
35. Wood W, Tron V. Analysis of HMB-45 immunoreactivity in common and cellular blue nevi. J Cutan Pathol 1991;18:261-3.
36. Zimmer C, Gottschalk J, Goebel S, Cercos-Navarro J. Melanoma-associated antigens in tumors of the nervous system: an immunohistochemical study with the monoclonal antibody HMB-45. Virchows Arch 1992;420:121-6.